Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
European Journal of Immunology
|
August 1, 1993
T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides
D Kyburz, P Aichele, D E Speiser, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 8, 1999
Human rheumatoid factor production is dependent on CD40 signaling and autoantigen
D Kyburz, M Corr, D C Brinson, et al.
Zeitschrift Fur Rheumatologie
|
June 29, 2006
[Evidence-based therapy of Raynaud's syndrome]
M Distler, J Distler, A Ciurea, et al.
The Journal of Experimental Medicine
|
May 1, 1992
Clonal deletion induced by either radioresistant thymic host cells or lymphohemopoietic donor cells at different stages of class I-restricted T cell ontogeny
D E Speiser, H Pircher, P S Ohashi, et al.
Annals of the Rheumatic Diseases
|
March 17, 2006
Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study
L Brulhart, A Ciurea, A Finckh, et al.
Scandinavian Journal of Rheumatology
|
August 17, 2017
Calcium pyrophosphate deposition disease: a frequent finding in patients with long-standing erosive gout
B Ankli, D Kyburz, A Hirschmann, et al.
Swiss Medical Weekly
|
April 12, 2014
Biological agents in monotherapy for the treatment of rheumatoid arthritis
C Gabay, P Hasler, D Kyburz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 18, 1994
Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model
P Aichele, D Kyburz, P S Ohashi, et al.
Rheumatology (Oxford, England)
|
April 12, 2007
The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis
M Pierer, F Brentano, J Rethage, et al.
Annals of the Rheumatic Diseases
|
May 7, 2009
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
A Finckh, A Ciurea, L Brulhart, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
European Journal of Immunology
|
August 1, 1993
T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides
D Kyburz, P Aichele, D E Speiser, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 8, 1999
Human rheumatoid factor production is dependent on CD40 signaling and autoantigen
D Kyburz, M Corr, D C Brinson, et al.
Zeitschrift Fur Rheumatologie
|
June 29, 2006
[Evidence-based therapy of Raynaud's syndrome]
M Distler, J Distler, A Ciurea, et al.
The Journal of Experimental Medicine
|
May 1, 1992
Clonal deletion induced by either radioresistant thymic host cells or lymphohemopoietic donor cells at different stages of class I-restricted T cell ontogeny
D E Speiser, H Pircher, P S Ohashi, et al.
Annals of the Rheumatic Diseases
|
March 17, 2006
Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study
L Brulhart, A Ciurea, A Finckh, et al.
Scandinavian Journal of Rheumatology
|
August 17, 2017
Calcium pyrophosphate deposition disease: a frequent finding in patients with long-standing erosive gout
B Ankli, D Kyburz, A Hirschmann, et al.
Swiss Medical Weekly
|
April 12, 2014
Biological agents in monotherapy for the treatment of rheumatoid arthritis
C Gabay, P Hasler, D Kyburz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 18, 1994
Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model
P Aichele, D Kyburz, P S Ohashi, et al.
Rheumatology (Oxford, England)
|
April 12, 2007
The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis
M Pierer, F Brentano, J Rethage, et al.
Annals of the Rheumatic Diseases
|
May 7, 2009
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
A Finckh, A Ciurea, L Brulhart, et al.
Page
of 3